Loading resource…

School of Cardiovascular and Metabolic Health, BHF Glasgow Cardiovascular Research Centre, University of Glasgow
The article aims to provide a comprehensive review of current key guidelines for managing high-risk patients with diabetes and heart failure. It scrutinizes major recommendations, particularly highlighting the role of sodium-glucose co-transporter 2 inhibitors (SGLT2i) as recommended treatments for symptomatic heart failure. The document also discusses future prospects in the management of these patients, emphasizing the importance of tailored therapeutic strategies.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology

PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology

OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology

CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology

The Athlete’s ECG
Same clinical topic · Cardiology

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology

Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology

Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology

INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology